[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100490893":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":21,"responsibleParty":39,"collaborators":7,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":65,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Tao Jiang, MD","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+8613501306106","doctorjiangtt@163.com",{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},"Yahui Zhao, MD","+8618519325917","yahuii.zhao@hotmail.com",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Beijing Tiantan Hosiptal","RECRUITING","Beijing","Beijing Municipality","100050","China","CN",{"type":31,"coordinates":32},"Point",[33,34],116.39723,39.9075,{"lat":34,"lon":33},[37],{"name":38,"role":14,"phone":7,"phoneExt":7,"email":16},"Tao Jiang",{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100490893","genetic-and-molecular-risk-profiles-of-pediatric-malignant-brain-tumors-in-china-100490893",false,"NCT05672043","Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China","Perspective Study on Genetic Predispositions and Clinical Prognosis of Children and Adolescents With Malignant Brain Neoplasms in China","GRIPP","Inclusion Criteria:\n\n\\- Children and adolescents aged between 0-18 years old, diagnosed with medulloblastoma or other malignant central nervous system tumors including glioma, ependymoma, germ cell tumors,tuberous sclerosis, neuronal and neuronoglial tumors, choroid plexus tumors, atypical teratoid\u002Frhabdoid tumors, ependymoblastoma, and medulloepithelioma;\n\nPatients must be eligible for and receive tumor resection;\n\nHistological examination by institutional neuro-pathological evaluation must confirmed the diagnosis of brain malignancies;\n\nParticipants consent with joining the current study and comply with follow-up visits;\n\nThe patients must have no previous radiotherapy or chemotherapy other than corticosteroids.\n\nExclusion Criteria:\n\n\\- Patients with major perioperative complications which lead to significant and sudden deterioration;\n\nPatients with major systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) which might compromise the patient's ability to tolerate standard treatment or would likely interfere with overall prognosis;\n\nPatients with major adverse events or sudden deterioration irrelevant to the current study;\n\nQuality of tumor tissue sample did not meet the criterion for genetic sequencing and laboratory investigations;\n\nPatients who refuse to participate in the study or who request dropping out from the study","ALL","0 Years","18 Years",{"count":53,"type":54},400,"ESTIMATED","5 Years","OBSERVATIONAL","Primary malignant central nervous system (CNS) tumors are the second most common childhood malignancies. Amongst, medulloblastomas are the most common malignant brain tumor of childhood and occur primarily in the cerebellum. According to molecular characteristics, medulloblastomas were classified into four subtypes: WNT, SHH, Group3 and Group4 and different prognosis were noticed between subgroups. Several genetic predispositions related to clinical outcome were also discovered and might influence the treatment of medulloblastomas as novel pharmaceutical targets. This study aims to investigate genetic and cellular profiles of pediatric brain malignancies, mostly medulloblastomas, and other central nervous system tumor based on WGS, RNA-seq, single-cell sequencing and spatial transcriptomics. We also aim to investigate the correlation between genetic characteristics and clinical prognosis.",[59,60,61,62,63,64],"Medulloblastoma","Central Nervous System Tumor, Pediatric","Ependymoma","Germ Cell Tumor","Glioma","Brain Tumor, Pediatric",[66,67],"medulloblastoma","pediatric brain tumor","2023-01-03",{"date":70,"type":71},"2023-01-05","ACTUAL",{"date":73,"type":71},"2023-01-01",{"date":75,"type":54},"2032-12-31",{"name":5,"class":6},1]